share_log

騰盛博藥-B：截至2023年12月31日之股份發行人的證券變動月報表

BRII-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023

香港交易所 ·  Jan 5 03:05
Summary by Moomoo AI
腾盛博药生物科技有限公司於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本結存維持在1,200,000,000股，每股面值0.000005美元，總額6,000美元，本月無變動。此外，公司的股份期權計劃下，有部分股份期權已失效，包括2018年和2021年採納的股份激勵計劃及購股權計劃。報告亦提到，公司於2022年1月至2023年8月期間，根據股份獎勵計劃授出了多批受限制股份單位，並將以公司現有一般授權發行的新股份作出。2023年12月，共有415,600份受限制股份單位失效，並有4,107份受限制股份單位被註銷。本月普通股增加總數為19,393股。
腾盛博药生物科技有限公司於2024年1月5日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報告顯示，公司的法定/註冊股本結存維持在1,200,000,000股，每股面值0.000005美元，總額6,000美元，本月無變動。此外，公司的股份期權計劃下，有部分股份期權已失效，包括2018年和2021年採納的股份激勵計劃及購股權計劃。報告亦提到，公司於2022年1月至2023年8月期間，根據股份獎勵計劃授出了多批受限制股份單位，並將以公司現有一般授權發行的新股份作出。2023年12月，共有415,600份受限制股份單位失效，並有4,107份受限制股份單位被註銷。本月普通股增加總數為19,393股。
TENSHENG BO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. FILED WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 5 JANUARY 2024 THE REPORT OF CHANGES IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023. The report showed that the company's regulated/registered capital deposit remained at 1,200,000,000 shares with a face value of $0.00000005 per share for a total of $6,000, unchanged this month. In addition, some share options have lapsed under the Company's stock option plan, including the Share Incentive Schemes and Share Option Plans adopted in 2018 and 2021. The report also noted that the Company issued multiple units of restricted shares under the Share Award Scheme between January 2022 and August 2023 and will issue new shares under the Company's existing general authorization. In December 2023, a total of 415,600 units of restricted shares expired and 4,107 restricted units were written off. The total number of ordinary shares increased to 19,393 shares this month.
TENSHENG BO PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. FILED WITH HONG KONG TRADING AND SETTLEMENT LIMITED ON 5 JANUARY 2024 THE REPORT OF CHANGES IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023. The report showed that the company's regulated/registered capital deposit remained at 1,200,000,000 shares with a face value of $0.00000005 per share for a total of $6,000, unchanged this month. In addition, some share options have lapsed under the Company's stock option plan, including the Share Incentive Schemes and Share Option Plans adopted in 2018 and 2021. The report also noted that the Company issued multiple units of restricted shares under the Share Award Scheme between January 2022 and August 2023 and will issue new shares under the Company's existing general authorization. In December 2023, a total of 415,600 units of restricted shares expired and 4,107 restricted units were written off. The total number of ordinary shares increased to 19,393 shares this month.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more